ESC 2026: Biomarker indicates coronary inflammation from non-contrast CT

Caristo's FAI biomarker demonstrated its role in assessing coronary inflammation from non-contrast CT scans and in predicting cardiovascular death. Caristo's FAI biomarker demonstrated its role in assessing coronary inflammation from non-contrast CT scans and in predicting cardiovascular death. Cardiovascular disease is the world’s leading cause of death, as per the World Health Organization (WHO). Credit: ridersuperone/Shutterstock.com New research led by the University of Oxford has validated Caristo Diagnostics’ fat attenuation index-score (FAI) biomarker’s role in coronary inflammation assessment, suggesting future applications for the company’s CaRi-Heart technology. Findings from two separate analyses of Caristo’s ORFAN study (NCT05169333) on predicting future stroke…

Source: Medical Device Network